Back to Search
JEFFREY LANCET, MD
MD
Hematology & Oncology Physician
NPI: 1831110337IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
ME91554(FL)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Novel postremission strategies in adults with acute myeloid leukemia.
PMID 19468272·Curr Opin Hematol·2009
6-review
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
PMID 19108889·Leuk Res·2009
3-trial
Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant.
PMID 19176199·J Natl Compr Canc Netw·2008
6-review
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
PMID 17082323·Blood·2007
3-trial
Farnesyl transferase inhibitors in myeloid disorders.
PMID 16131046·Oncology (Williston Park)·2005
4-observational
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.
PMID 19543327·Bone Marrow Transplant·2010
8-other
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
PMID 18976810·Leuk Res·2009
3-trial
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.
PMID 19398716·Blood·2009
3-trial
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
PMID 18160667·Blood·2008
3-trial
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
PMID 17404110·Clin Cancer Res·2007
3-trial
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
PMID 17882662·Cancer Invest·2007
6-review
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
PMID 17351110·Blood·2007
3-trial
Acute myeloid leukemia clinical practice guidelines in oncology.
PMID 16403402·J Natl Compr Canc Netw·2006
6-review
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
PMID 16321813·Hematology·2005
8-other
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
PMID 16556050·Future Oncol·2005
6-review
Targeting the process of farynesylation for therapy of hematologic malignancies.
PMID 16305490·Curr Mol Med·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12902 USF MAGNOLIA DR
TAMPA, FL 33612 - Phone
- (813) 745-4673
Quick Facts
- NPI
- 1831110337
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile